Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Amgen : R&D Head Dr. David Reese Shares Perspective on COVID-19

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2020 | 10:09am EDT

Dr. David Reese, Amgen's Head of R&D, recently shared his perspective on the COVID-19 pandemic from his home office. Dr. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco. His remarks contextualize some of the decisions that governments and companies like Amgen are making in the interest of public health. Reese also talks about the importance of social distancing and personal hygiene.

Disclaimer

Amgen Inc. published this content on 20 March 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 March 2020 15:08:02 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN INC.
05/20AMGEN : Science, Execution, and COVID-19 Response Highlighted at Annual Stockhol..
PU
05/20AMGEN : Announces Voting Results Of Annual Meeting Of Stockholders
PR
05/20AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/20AMGEN : Investor Insights Newsletter Q1 2020
PU
05/19AMGEN : Q4 2019 Financial Results
PU
05/15AMGEN INC. : Ex-dividend day for
FA
05/13AMGEN : Dancing and Kickboxing to Stay Fit Between Conference Calls
PU
05/13AMGEN : Showcases Oncology Pipeline At ASCO 2020
PR
05/12AMGEN : To Present At The Bank Of America Merrill Lynch Virtual Global Healthcar..
PR
05/12Lundbeck boosted by stockpiling, launches key drug remotely
RE
More news
Financials (USD)
Sales 2020 25 316 M
EBIT 2020 11 986 M
Net income 2020 7 302 M
Debt 2020 23 293 M
Yield 2020 2,77%
P/E ratio 2020 18,0x
P/E ratio 2021 15,9x
EV / Sales2020 6,18x
EV / Sales2021 5,83x
Capitalization 133 B
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 251,44 $
Last Close Price 226,43 $
Spread / Highest target 28,5%
Spread / Average Target 11,0%
Spread / Lowest Target -18,3%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.-6.07%133 197
JOHNSON & JOHNSON-1.03%380 356
ROCHE HOLDING AG10.48%303 907
PFIZER, INC.-4.29%208 306
MERCK & CO., INC.-16.03%192 766
NOVARTIS AG-10.58%186 299